Skip to main content
OpenTrials
Completed

NCT Number: NCT00308503

Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia

The aim of the study is to confirm the efficacy of eplivanserin 5mg/day on sleep maintenance of patients with primary insomnia using night polysomnography recordings over a 6-week treatment period corresponding to a stabilization of improvement of sleep.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Sanofi-Aventis, Macquarie Park, New South Wales, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for at least one month preceding the study visit.
  • Disturbance of sleep maintenance:
  • Based on patient' s information:
  • Patient has spent at least 6.5 hours and not more than 9.0 hours, in bed, each night, over the preceding two weeks,
  • Patient must complain of at least one hour of wakefulness after sleep onset for at least 3 nights per week over the preceding month,
  • Patient must report impact on daytime functioning associated with sleep maintenance insomnia

Inclusion will be based on the nocturnal polysomnography (NPSG) recordings performed at the sleep laboratory during the two screening nights.

Exclusion criteria

  • Females who are lactating or who are pregnant, or of childbearing potential not using an acceptable form of contraception
  • Patients presenting with acute or chronic pain resulting in insomnia
  • Patients with current psychiatric disturbances
  • Body mass index > 32
  • Evidence of any clinically significant, severe or unstable, acute or chronically progressive medical or surgical disorder, or any condition that may interfere with the absorption, metabolism, distribution or excretion of the study drug, or may affect patient safety
  • Clinically significant and abnormal electrocardiogram (ECG) (including QTc B > 500ms),
  • A positive test for hepatitis B (hepatitis B surface [HBs] antigens) or C (hepatitis C virus [HCV] antibodies)
  • Positive qualitative urine drug screen at screening
  • Consumption of xanthine-containing beverages (i.e. tea, coffee, or cola) comprising usually more than 5 cups or glasses per day
  • Use of any over-the-counter or prescription sleep medication, or of any substance with psychotropic effects or properties known to affect sleep/wake, within one week or five half-lives (whichever is longer), prior to screening
  • Night shift workers, and individuals who nap 3 or more times per week over the preceding month
  • Based on medical history and/or NPSG:
  • primary hypersomnia
  • narcolepsy
  • breathing-related sleep disorder (apnea-hypopnea index > 10/hour of sleep)
  • circadian rhythm sleep disorder
  • parasomnia (e.g. somnambulism)

Treatment and study plan

Eplivanserin (SR46349)

Drug

oral administration

Placebo

Drug

oral administration

Primary outcomes

  1. Change from baseline of night polysomnography Wake Time After Sleep Onset (PSG WASO)

    Time frame: week 6

Secondary outcomes

  1. Change from baseline in general productivity domain of the FOSQ (Functional Outcome of Sleep Questionnaire)

    Time frame: week 6

  2. Change from baseline in patient reported wake after sleep onset (pr-WASO)

    Time frame: week 6

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Official study title

Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: A 6 Week, Multicenter, Randomized, Double -Blind, Placebo-controlled Study

Acronym: EPOCH

Important dates

Study start
2006
Primary completion
2007
Study completion
2007
First posted
Mar 29, 2006
Registry last updated
Nov 30, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.